Live Breaking News & Updates on Alison Schram

Stay updated with breaking news from Alison schram. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC

Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial. ....

Memorial Sloan Kettering Cancer Center , New York , United States , Alison Schram , Beigene Springworks , Us Food Drug Administration , Relay Therapeutics , Blueprint Bio , Flagship Pioneering , Redona Therapeutics , Black Diamond Therapeutics , Elevation Oncology , Northern Biologics , Repare Therapeutics , Revolution Medicines , Surface Oncology , Kimd W , Nrg1 Fusions , Phase 1 2 Enrgy Trial , Cla 128 ,

2023-10-23 | NDAQ:MRUS | Press Release

(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer ....

United Kingdom , Andrew Joe , Alison Schram , Zeno Closecurlyquote , Early Access Program , Memorial Sloan Kettering Cancer Center , Corporate Communications , Exchange Commission , European Society For Medical Oncology , Company Closecurlydoublequote , Principal Investigator , European Society , Medical Oncology , Chief Medical Officer , Merus Closecurlyquote , Merus Dock , Private Securities Litigation Reform Act , Factors Closecurlydoublequote , Quarterly Report , Media Inquiries , Corp Comms , Merus Nv , Healthcare 37 , Biotechnology 121 , Usa 8 , Biotechnology 70569 ,

Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer Seite 1

23.10.2023 - - 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The . Seite 1 ....

United Kingdom , Alison Schram , Andrew Joe , European Society For Medical Oncology , Early Access Program , Memorial Sloan Kettering Cancer Center , Principal Investigator , European Society , Medical Oncology , Chief Medical Officer , Merus Chart , Erus Kurs , Erus Aktie ,

Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer -October 23, 2023 at 07:31 am EDT

- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to. ....

United Kingdom , Andrew Joe , Alison Schram , Exchange Commission , Early Access Program , Memorial Sloan Kettering Cancer Center , European Society For Medical Oncology , Principal Investigator , European Society , Medical Oncology , Chief Medical Officer , Merus Dock , Private Securities Litigation Reform Act , Quarterly Report ,

Merus Announces Business Update Conference Call

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA. ....

United Kingdom , United States , Andrew Joe , Zenocutuzumab Zeno , Alison Schram , Early Access Program , European Society For Medical Oncology Congress , Company Conference Call , Sasia Congress , American Association Of Cancer Research Annual Meeting , Exchange Commission , Memorial Sloan Kettering Cancer Center , European Society , Medical Oncology Congress , Principal Investigator , Spain October , Chief Medical Officer , Oral Presentation Title , Presentation Details , Presentation Title , Poster Session , American Association , Cancer Research Annual Meeting , Bill Lundberg , Chief Executive Officer , Singapore December ,